P-G3 PAMAM

P-G3 PAMAM (polyamidoamine generation 3) is a positively charged (cationic) dendrimer nanomolecule originally developed by researchers at Columbia University and licensed/developed by Sable Therapeutics. It is designed to selectively target adipose tissue (specifically visceral fat) through charge-based interactions with the negatively charged extracellular matrix (ECM) of white adipose tissue. In preclinical models, P-G3 PAMAM uncouples lipid synthesis and storage from adipocyte development, reducing fat-cell volume and lipid accumulation without causing cytotoxicity. It is being explored for both therapeutic applications in obesity and metabolic diseases, as well as cosmetic applications (under the trade name Adicel) for localized fat reduction and improving the visible appearance of body skin.

Brand names

Adicel

Other names

Generation-3 polyamidoamine dendrimerGeneration3 polyamidoamine dendrimerGeneration 3 polyamidoamine dendrimerP-G3 polyamidoamineP-G-3 polyamidoamineP-G 3 polyamidoaminePAMAM generation 3polyamidoamine generation 3